ACC 2006

Single Agent Bivalirudin Better for Acute Coronary Syndromes

Gregg Stone
Gregg Stone, Columbia University Medical Center, New York
American College of Cardiology Annual Scientific Session March 11-14, 2006, Atlanta
A superiority for the anti-clotting drug bivalirudin for treating patients with acute coronary syndromes was detected when this was used as monotherapy, but not when this direct thrombin inhibitor was combined with glycoprotein IIb/IIIa inhibition. Thus found the ACUITY trial reported to the ACC’s Atlanta meeting by Gregg Stone of Columbia University. He told Audio Medica the bottom line finding from the study.

Similar Interviews

  • Audio Journal of Cardiovascular Medicine: June 2006 - In the company of Michael Petch">Audio Journal of Cardiovascular Medicine: June 2006 - In the company of Michael Petch
  • Annual Meeting of the American College of Cardiology March 11-14, 2006, Atlanta: Single Agent Bivalirudin Better for Acute Coronary Syndromes;

  • Fewer Major Bleeding Events with Bivalirudin For Patients with Acute Coronary Syndromes: The ACUITY study
  • HARVEY WHITE, Auckland City Hospital, New Zealand REFERENCE: ACUITY Trial, ACC.07 Scientific Session and i2 Innovations Summit. Presentation Number: 2414-5 Patients with

  • Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?
  • Freek Verheugt Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy,

    Post a comment

    Subscribe to Audio Medica Podcast